Asklepios: preliminary figures for 2011
Increase of more than nine percent in number of cases
Asklepios Kliniken have expanded their position substantially by increasing their share in MediClin AG to over 52 percent. Moreover, in the past year, patient numbers recorded a significant increase to more than 1.7 million, a rise of 9.1 percent.
Total turnover increased by a good 12 percent to €2.557 billion. Whilst approximately one third was the result of organic growth, two thirds of the increase in turnover were due to the takeover of MediClin AG. Due to the difficult overall economic environment, the significant rise in material and personnel costs as well as non-recurring expenditure, it was not possible to sustain EBITDA which, at €217.2 million, is slightly below the previous year’s level.
“The Asklepios Group has strong internal financing capabilities at its disposal. Even after the majority acquisition of MediClin, the balance sheet and financing structures are sound, balanced and orientated towards long-term development. We intend to continue to pursue our growth course in the current business year too, and expect a turnover of some three billion euros. At the same time, one of our medium-term aims is to achieve a sustainable increase in EBITDA in the direction of €300 million by means of synergies,” states Stephan Leonhard, Vice President of Corporate Management and CFO.